MedTrace Logo

Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin

NCT01613729 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2012-09-25

No results posted yet for this study

Summary

The primary objective of the study is to compare the efficacy of Rosuvastatin 5 mg once daily with Rosuvastatin 10 mg once daily by assessment of the number of patients with hypercholesterolemia reaching the LDL-C target goal of \<100 mg/dL after 12 weeks of therapy.

Conditions

Interventions

DRUG

Rosuvastatin 5 mg

Rosuvastatin 5 mg

DRUG

Rosuvastatin 10 mg

Sponsors & Collaborators

  • Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

    collaborator OTHER

  • Dhaka Medical College

    collaborator OTHER

  • National Institute of Cardiovascular Diseases

    collaborator UNKNOWN

  • D16 Pharma & Biotec Ltd.

    lead INDUSTRY

Principal Investigators

  • Nazrul Islam, FCPS · Professor of Cardiology

  • Pinaki Bhattacharya, MBBS · D16 Pharma & Biotec

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-07-31
Completion
2013-12-31

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01613729 on ClinicalTrials.gov